PersImmune, Inc Report issue

For profit Phase 1
Founded: San Diego CA United States (2010)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03258359
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

PersImmune, Inc

Active Ingredients

Drugs in Phase 1 Trials (1)

pactn (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myelodysplastic Syndromes (Phase 1)

Preleukemia (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1